# Phase-III Clinical Studies on Poly Herbal Anti-Diabetic Formulation

Study · id `cardio:ct-nct07279909` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07279909](<https://clinicaltrials.gov/study/NCT07279909>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07279909

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 500 participants.

## Technical summary

Registry record NCT07279909. Non-randomized; no masking; primary purpose treatment. Start 2024-03-09 (actual); primary completion 2025-08-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 500 participants (enrolled count; ClinicalTrials.gov record NCT07279909, source copy `cardio:ctgov-nct07279909-2025-12-12`, retrieved 2026-10-26)
- Started: 2024-03-09 (actual) (ClinicalTrials.gov record NCT07279909, source copy `cardio:ctgov-nct07279909-2025-12-12`, retrieved 2026-10-26)
- Primary completion: 2025-08-01 (actual) (ClinicalTrials.gov record NCT07279909, source copy `cardio:ctgov-nct07279909-2025-12-12`, retrieved 2026-10-26)
- Completion: 2026-05-20 (anticipated) (ClinicalTrials.gov record NCT07279909, source copy `cardio:ctgov-nct07279909-2025-12-12`, retrieved 2026-10-26)
- Countries: Pakistan (ClinicalTrials.gov record NCT07279909, source copy `cardio:ctgov-nct07279909-2025-12-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07279909-2025-12-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase-III Clinical Studies on Poly Herbal Anti-Diabetic Formulation
- Condition: Diabetes Type 2
- Condition: Diabetes Mellitus, Experimental
- Condition: HbA1c
- Condition: Urinary Glucose
- Condition: Ability of Experimental Drug to Lower HbA1c Compare to Metformin
- Intervention (Drug): DIAB-PHC1
- Intervention (Drug): Metformin
- Lead sponsor: Hamdard University
- Lead sponsor class: OTHER
- Collaborator: Jinnah Postgraduate Medical Centre
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 972256e2a2a99a8565dd0ec9b87aded91ab9a6c873413f9df2ac3164ccc85ae3
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
